Trial Profile
A Study in Patients With Chorioretinal Vascular Disease to Evaluate an Aflibercept (EYLEA) Prefilled Syringe
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion; Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 06 Oct 2020 Status changed from active, no longer recruiting to completed.
- 11 Aug 2020 Planned End Date changed from 17 Jul 2020 to 19 Aug 2020.
- 11 Aug 2020 Planned primary completion date changed from 16 Jul 2020 to 19 Aug 2020.